Oculis Holding AG (OCS) Change in Account Payables (2022 - 2024)
Oculis Holding AG (OCS) posted quarterly Change in Account Payables of $2.5 million for Q4 2024, up 188.29% year-over-year from $851726.4 in Q1 2024, and up 23.68% quarter-over-quarter from $2.0 million in Q3 2024.
Analysis
Oculis Holding AG (OCS) Change in Account Payables (2022 - 2024) Analysis & Trends
Oculis Holding AG's Change in Account Payables history runs 3 years deep, the most recent figure standing at $2.5 million for Q4 2024.
- In Q4 2024, Change in Account Payables rose 188.29% year-over-year to $2.5 million; the TTM figure through Dec 2024 stood at -$514032.6 (down 200.93% YoY), while the FY2024 annual figure was -$429673.2, down 202.09% from the prior year.
- Change in Account Payables for Q4 2024 stood at $2.5 million, up from $2.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $3.5 million in Q4 2022, with the low at -$7.4 million in Q1 2024.
- The 3-year median for Change in Account Payables is $2.1 million (2023), against an average of $266803.2.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 527.44% in 2023, then tumbled 215.5% in 2024.
- Oculis Holding AG's Change in Account Payables stood at $3.5 million in 2022, then sank by 180.36% to -$2.8 million in 2023, then surged by 188.29% to $2.5 million in 2024.
- Business Quant data shows OCS's Change in Account Payables at $2.5 million in Q4 2024, $2.0 million in Q3 2024, and $2.4 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | -7.36 Mn |
| Dec 31, 2023 | -2.78 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Sep 30, 2022 | -787,982.50 |